ERBB2 and cancer: Phospho-signaling is increased in cancer, often in a cell-intrinsic manner by oncogenic mutations in signaling pathways (e.g., RAS or HER2), but also through cell-extrinsic signals from the tumor microenvironment (e.g., TGFβ or FGF).